Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14571889 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL14606210 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL5598863 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL5598404 | 1.00 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL9458781 | 0.86 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL4071198 | 0.86 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL1692473 | 0.86 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL2533818 | 0.86 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL6689012 | 0.86 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 | |
| SCHEMBL15307543 | 0.86 | EPHX1 (0.67) | EPHX1TSHRMEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | EPHX1 3776/4885TSHR 4243/4885MEN1 1363/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | EPHX1 3938/4885TSHR 4710/4885MEN1 2595/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | EPHX1 3271/4885TSHR 4278/4885MEN1 3638/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | EPHX1 3776/4885TSHR 4243/4885MEN1 1363/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | EPHX1 3271/4885TSHR 4278/4885MEN1 3638/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | EPHX1 3776/4885TSHR 4243/4885MEN1 1363/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | EPHX1 3938/4885TSHR 4710/4885MEN1 2595/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | EPHX1 3776/4885TSHR 4243/4885MEN1 1363/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | EPHX1 3776/4885TSHR 4243/4885MEN1 1363/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | EPHX1 3938/4885TSHR 4710/4885MEN1 2595/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | EPHX1 3074/4885TSHR 4429/4885MEN1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.